2 Breakthrough Vaccines Command Investor Focus
Pharma investors tired of a patent cliff can turn toward vaccine focused businesses. And we recently saw two new breakthrough meningitis vaccines from Pfizer (NYSE: PFE) and Novartis (NYSE: NVS) file for FDA approval.
What is exciting about these new products is their ability to vaccinate for meningitis B. Pfizer is hoping to add an incremental $500 million in sales, but Novartis may not realize any of its success. GlaxoSmithKline (NYSE: GSK) recently bulked up its vaccine business with a $7.1 billion deal with Novartis that included its meningitis portfolio.
In this episode of Market Check-Up, the Motley Fool's health care focused investing show, analysts David Williamson and Michael Douglass, discuss the trial data, why vaccines are increasingly attractive to big pharma and which one has the biggest potential.
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
The article 2 Breakthrough Vaccines Command Investor Focus originally appeared on Fool.com.David Williamson owns shares of Novartis and Pfizer. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.